Company: BIAF
Filing Date: 2025-05-27
Form Type: 424B5
Source: 0001641172-25-012410
Chunk: 18

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-27
Form: 424B5
Chunk 18
---
 a warrant inducement private placement and a registered direct offering and concurrent private placement, all of which were consummated in August 2024, (v) as placement agent for a registered direct offering and concurrent private placement consummated in October 2024, (vi) as financial advisor for the Warrant Inducement consummated in February 2025, and (vii) as placement agent for a best efforts public offering consummated in May 2025, pursuant to which WallachBeth received cash compensation and warrants. To the extent required by Regulation M, WallachBeth will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus.

The foregoing does not purport to be a complete
statement of the terms and conditions of the Sales Agreement. A copy of the Sales Agreement is included as an exhibit to our Current
Report on Form 8-K that will be filed with the SEC and incorporated by reference into the registration statement of which this prospectus
supplement and the accompanying base prospectus form a part.

| S-8 |

<div align='center'>LEGAL MATTERS</div>

The validity of the shares of common stock offered hereby will be passed upon for us by Blank Rome LLP, New York, New York. Sichenzia Ross Ference Carmel LLP, New York, New York, is acting as counsel to the Sales Agent in this offering.

<div align='center'>EXPERTS</div>

The consolidated financial statements of bioAffinity Technologies, Inc. as of December 31, 2024 and 2023, and for the years ended December 31, 2024 and 2023, appearing in this prospectus supplement and registration statement have been audited by WithumSmith+Brown, PC, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about bioAffinity Technologies, Inc.’s ability to continue as a going concern as described in Note 1 to the consolidated financial statements) appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

<div align='center'>WHERE YOU CAN FIND MORE INFORMATION</div>

This prospectus supplement and the accompanying base prospectus is part of a registration statement we filed with the SEC. This prospectus supplement does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information